Ipsen supplier Lonza has successfully re-manufactured the API of Increlex (mecasermin [rDNA origin] Injection) and Ipsen has informed the EMA that it is preparing for the resupply of Increlex in the EU. Consultations with the EU Member States’ national competent authorities are now in process to allow immediate resupply. Resupply in the U.S. is still pending. Ipsen has been actively managing the shortage period in the U.S. to reduce its impact on patients. Increlex is used to treat patients wit...